A Cell-Based Potency Assay for Determining the Relative Potency of Botulinum Neurotoxin A Preparations Using Manual...

Area of Science:

• Biotechnology
• Pharmacology
• Analytical Chemistry

Background:

• Cell-based potency assays (CBPAs) are critical for the regulatory approval and commercialization of botulinum neurotoxin (BoNT) therapeutics.
• Existing assays must balance biological activity measurement with stringent regulatory requirements for precision and accuracy.

Purpose of the Study:

• To characterize and qualify the BoSapient CBPA for relative potency testing of BoNT/A drug products.
• To demonstrate the assay's suitability for regulatory compliance and commercial release.

Main Methods:

• Development of a 96-well plate CBPA utilizing a reporter responsive to BoNT/A activity.
• Engineering the BoSapient cell line to express BoNT/A receptors (SV2, complex gangliosides) for specific detection.
• Qualification of manual and semi-automated assay methods according to regulatory guidelines.

Main Results:

• The BoSapient cell line demonstrated high sensitivity, detecting picomolar and sub-picomolar BoNT/A concentrations.
• The cell line maintained reporter expression and BoNT/A sensitivity over 30 passages.
• Both manual and semi-automated methods exhibited low bias (<4%) and high precision (SD < 8).
• The semi-automated method improved intermediate precision by 39% and reduced operator dependency.

Conclusions:

• The BoSapient CBPA is a validated and robust assay suitable for the relative potency testing of BoNT/A drug products.
• The assay meets regulatory guidelines for precision and accuracy, facilitating commercial release.
• Semi-automation enhances assay performance and reduces variability, making it advantageous for routine use.